These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24074918)

  • 1. Correlation of Smad4 status with outcomes in patients receiving erlotinib combined with adjuvant chemoradiation and chemotherapy after resection for pancreatic adenocarcinoma.
    Herman JM; Fan KY; Wild AT; Wood LD; Blackford AL; Donehower RC; Hidalgo M; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):458-9. PubMed ID: 24074918
    [No Abstract]   [Full Text] [Related]  

  • 2. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation.
    Herman JM; Jabbour SK; Lin SH; Deek MP; Hsu CC; Fishman EK; Kim S; Cameron JL; Chekmareva M; Laheru DA; Narang AK; Pawlik TM; Hruban RH; Wolfgang CL; Iacobuzio-Donahue CA
    Pancreas; 2018 Feb; 47(2):208-212. PubMed ID: 29329157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma.
    Fei N; Wen S; Ramanathan R; Hogg ME; Zureikat AH; Lotze MT; Bahary N; Singhi AD; Zeh HJ; Boone BA
    Clin Transl Sci; 2021 Sep; 14(5):1822-1829. PubMed ID: 34002944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Redefining the Positive Margin in Pancreatic Cancer: Impact on Patterns of Failure, Long-Term Survival and Adjuvant Therapy.
    Osipov A; Nissen N; Rutgers J; Dhall D; Naziri J; Chopra S; Li Q; Hendifar AE; Tuli R
    Ann Surg Oncol; 2017 Nov; 24(12):3674-3682. PubMed ID: 28871564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we move towards personalised pancreatic cancer therapy?
    Jamieson NB; Chang DK; Grimmond SM; Biankin AV
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):335-8. PubMed ID: 24702631
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
    Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
    Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
    Takahashi H; Akita H; Gotoh K; Kobayashi S; Marubashi S; Miyoshi N; Sugimura K; Motoori M; Kishi K; Noura S; Fujiwara Y; Ohue M; Ohigashi H; Yano M; Sakon M; Ishikawa O
    Surgery; 2015 Mar; 157(3):484-95. PubMed ID: 25444512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
    Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
    J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
    Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
    Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
    Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
    Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Locally Advanced Pancreatic Ductal Adenocarcinoma.
    Loehrer AP; Kinnier CV; Ferrone CR
    Adv Surg; 2016 Sep; 50(1):115-28. PubMed ID: 27520867
    [No Abstract]   [Full Text] [Related]  

  • 13. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
    Singh P; Wig JD; Srinivasan R; Radotra BD
    Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
    Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
    Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the Impact of ESPAC-1 on Shifting the Paradigm of Pancreatic Cancer Treatment.
    Winer LK; Cortez AR; Ahmad SA; Wima K; Olowokure O; Latif T; Kharofa J; Patel SH
    J Surg Res; 2021 Mar; 259():442-450. PubMed ID: 33059910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
    Singh P; Srinivasan R; Wig JD
    Pancreas; 2012 May; 41(4):541-6. PubMed ID: 22504380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients.
    Paiella S; Malleo G; Cataldo I; Gasparini C; De Pastena M; De Marchi G; Marchegiani G; Rusev B; Scarpa A; Girelli R; Giardino A; Frigerio I; D'Onofrio M; Secchettin E; Bassi C; Salvia R
    Langenbecks Arch Surg; 2018 Mar; 403(2):213-220. PubMed ID: 28983662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy in pancreatic cancer.
    Jones OP; Melling JD; Ghaneh P
    World J Gastroenterol; 2014 Oct; 20(40):14733-46. PubMed ID: 25356036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.